PEPFAR’s Contribution to Laboratory

Diagnostics in the context of 90-90-90

Joel Kuritsky, MD

Dianna Edgil, PhD

Jason Williams, MPH

USAID Office of HIV/AIDS

March 10-11, 2016

2 Total lab spend $854,441,687

SCMS Non-Pharma Spend 2008-2015

3

SCMS Non-Pharma Spend 2008-2015

4

PEPFAR HIV POC Rapid Tests: Countries Served 2014-2015 (count of individual tests)

SCMS HIV RTKs Delivered

SCMS HIV RTKs Delivery, 2014-2015

GHSC-RTK HIV POC Rapid Test Pipeline (individual tests)

8

CD4 Instrument Totals

Molecular Instrument Totals

10

SCMS Total CD4 Spend (Oct 2015)

11

Total Molecular Spend—VL/EID (inclusive of instruments) (Oct 2015)

Molecular Instrument Totals

Coordination and Site Visits

• Coordinated procurement/forecasting

• Bundling of service maintenance/training with procurement

• With other TWGs—site visits December 2015—March 2016

• 1) Malawi—80k tests/11 platforms (sample rejection,

demand)

• 2) Uganda—200k tests/8 platforms (HR)

• 3) Swaziland—36k tests/2 platforms(HR, backlog, transport)

• 4) Kenya—750k/32 platforms (backlog)

• 5) Mozambique (pending)

• 6) Tanzania (pending) —14k tests/8 platforms

Achievements to Date in VL Scale up

Key Issues for COP16 Planning

VL scale up issues

1)Increasing instrument use/catch-up with backlog/switch from

CD4

2)Increasing responsibility of the manufacturers in

service/maintenance

3)HR/training/transport lanes

Quality assurance issues:

1)Collaboration with WHO PQ

2)Agreement with GDWG

PEPFAR’s Contribution to Laboratory

Diagnostics in the context of 90-90-90

Joel Kuritsky, MD

Dianna Edgil, PhD

Jason Williams, MPH

USAID Office of HIV/AIDS

March 10-11, 2016